secwatch.observer — SEC 8-K summary
======================================

Issuer:     PROKIDNEY CORP. (PROK)
CIK:        0001850270
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0000950170-24-124585
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA confirms PROACT 1 Phase 3 may support full approval; Q3 cash $406.8M
------------------------------------------------------------------------

- FDA Type B meeting confirms PROACT 1 Phase 3 could be sufficient for BLA; accelerated approval pathway available using eGFR slope as surrogate endpoint.
- Cash, equivalents and marketable securities $406.8M at Sept 30, 2024, expected to fund operations into 2027.
- Q3 2024 net loss before noncontrolling interest $41.1M vs $42.0M in Q3 2023; R&D $31.3M, G&A $17.7M including $5.3M impairment.
- Presented five posters at ASN Kidney Week including Phase 2 REGEN-007 late-breaking data.
- Shares outstanding: 291,661,950 Class A and B ordinary shares.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1850270/000095017024124585/0000950170-24-124585-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1850270/000095017024124585/prok-20241112.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-124585

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer